Balanced news tone
News Sentiment
PSNL sentiment intelligence
Personalis Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
News tone and price action are not far from neutral.
82/100 classification confidence.
directly relevant articles
high-authority source matches
+3.3% over one week, +46.7% over four weeks, trend active, and materially above fair value.
Personalis (PSNL) Recovers After Sale Speculation
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Personalis (PSNL) Recovers After Sale Speculation
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Jul 2026 21:46
- Source
- GuruFocus
TD Cowen Maintains Personalis(PSNL.US) With Buy Rating, Raises Target Price to $18
- Tone
- Positive 82/100
- Event
- Analyst action
- Published
- 16 Jul 2026 03:39
- Source
- Moomoo
Form 4 Personalis Inc For: 15 July By Investing.com
This article announced a Form 4 filing for Personalis Inc. (PSNL) on July 15th, 2026, noting that the stock was up 5.06% at the time of publication. The brief piece serves as a notice of the regulatory filing.
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 16 Jul 2026 01:10
- Source
- Investing.com Nigeria
[144] Personalis, Inc. SEC Filing
This article details a Form 144 SEC filing by Personalis, Inc. (PSNL), indicating a proposed sale of 100,000 shares of common stock with an aggregate market value of $1,503,000. The shares were acquired through the exercise of stock options on July 15, 2026, and the sale is expec
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jul 2026 20:42
- Source
- Stock Titan
Personalis president and CMO Richard Chen sells $1.5m in stock
Richard Chen, President and Chief Medical Officer of Personalis, Inc., sold 100,000 shares of company stock for $1.515 million after exercising options. The transaction was executed under a Rule 10b5-1 trading plan. The sale occurred as PSNL trades near its 52-week high, though I
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jul 2026 19:33
- Source
- Investing.com
PERSONALIS INC : TD COWEN RAISES TARGET PRICE TO $18 FROM $10
TD Cowen has increased its price target for Personalis Inc. (PSNL) shares from $10 to $18, while maintaining a "Buy" rating on the stock. This adjustment reflects a more optimistic outlook on the company's future stock performance.
- Tone
- Positive 72/100
- Event
- Analyst action
- Published
- 15 Jul 2026 16:10
- Source
- Moomoo
How UKCA Approval of NeXT Personal Dx Could Reshape Personalis’ (PSNL) Cross‑Border Cancer Trial Role
Personalis, Inc. recently received UKCA marking for its NeXT Personal Dx ultrasensitive MRD test, enabling its use in England, Wales, and Scotland, and has partnered with Link Medical Solutions for commercialization. This approval positions NeXT Personal Dx as a unified platform
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 14 Jul 2026 21:42
- Source
- Simply Wall Street
Personalis Receives UK Regulatory Marking for Disease Detection Technology
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 14 Jul 2026 10:40
- Source
- MT Newswires
Personalis (PSNL) Secures UKCA Marking for NeXT Personal Dx Test
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 Jul 2026 10:40
- Source
- GuruFocus
Personalis receives UK regulatory clearance for cancer test
Personalis Inc. has received UKCA marking for its NeXT Personal Dx test, allowing clinical use of its minimal residual disease detection technology in England, Wales, and Scotland. This regulatory clearance enables pharmaceutical companies to use the platform in multinational cli
- Tone
- Positive 72/100
- Event
- Regulatory and legal
- Published
- 14 Jul 2026 10:42
- Source
- Investing.com
Cancer Test for Small DNA Traces Can Now Be Used in Great Britain
Personalis, Inc. (Nasdaq: PSNL) has received UKCA marking for its NeXT Personal Dx test, allowing its advanced Minimal Residual Disease (MRD) detection technology to be used clinically across Great Britain. This regulatory milestone enables earlier cancer recurrence detection for
- Tone
- Positive 89/100
- Event
- Regulatory and legal
- Published
- 14 Jul 2026 09:42
- Source
- Stock Titan
Why Personalis Stock Is Rising: Medicare Covers Lung Cancer MRD Test
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 Jul 2026 06:46
- Source
- Stocktwits
Personalis Accelerates Global Expansion with UKCA Marking for NeXT Personal®, Expanding MRD Access and Biopharma Support in Great Britain
Personalis, Inc. has achieved UKCA marking for its NeXT Personal Dx test, allowing the clinical use of its ultrasensitive Minimal Residual Disease (MRD) detection technology across Great Britain. This regulatory milestone not only expands patient access to advanced cancer diagnos
- Tone
- Positive 74/100
- Event
- Regulatory and legal
- Published
- 14 Jul 2026 06:00
- Source
- Market source
PSNL Stock Climbs As Morgan Stanley Lifts Price Target
Personalis Inc. (PSNL) saw its stock climb by 10.2% after Morgan Stanley raised its price target from $9 to $13, signaling increased expectations ahead of the company's next earnings report. Despite the company's significant losses and negative profit margins, its strong liquidit
- Tone
- Positive 70/100
- Event
- Earnings
- Published
- 13 Jul 2026 16:39
- Source
- StocksToTrade
Enterprise value to EBITDA forward of Personalis, Inc. – HAM:04X
The article displays the enterprise value to EBITDA forward for Personalis, Inc. (HAM:04X) on the TradingView platform. It provides financial data and market information related to the company's stock on the Hamburg Stock Exchange. The content is presented within the context of T
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Jul 2026 00:11
- Source
- TradingView
Personalis's Clinical Growth Story Faces a Reality Check as CEO Sells Millions
Personalis (PSNL) stock has surged over 100% in the last year due to strong clinical growth and Medicare coverage for its NeXT Personal MRD test, pushing its market cap to $1.25 billion. However, CEO Christopher Hall recently sold over $2.8 million in stock, raising questions abo
- Tone
- Negative 36/100
- Event
- Market update
- Published
- 10 Jul 2026 21:39
- Source
- Kavout | AI
Personalis Insider Sold Shares Worth $1,508,000, According to a Recent SEC Filing
This article reports on a recent SEC filing indicating that an insider at Personalis sold shares valued at $1,508,000. Further details from the SEC filing would provide context on the specific insider, the number of shares, and the transaction date. This information is typically
- Tone
- Negative 20/100
- Event
- Market update
- Published
- 10 Jul 2026 08:10
- Source
- Moomoo
Personalis (PSNL) CEO trades 100,000 shares via 10b5-1 plan and option exercise
Personalis, Inc. CEO Christopher M. Hall reported exercising options for 100,000 shares at $1.61 each and subsequently selling those 100,000 shares at a weighted average price of $15.08 per share. These transactions, executed on July 9, 2026, were part of a pre-arranged Rule 10b5
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Jul 2026 01:09
- Source
- Stock Titan
Personalis (PSNL) Stock Looks Rich Even After A Very Large Run
Personalis (PSNL) stock has seen a significant 3-year gain, returning roughly 5x, yet its current valuation appears expensive based on fundamental checks. The company trades at a Price-to-Sales (P/S) ratio of 22.9x, far exceeding the industry average of 3.9x and a modelled fair P
- Tone
- Negative 19/100
- Event
- Market update
- Published
- 09 Jul 2026 21:39
- Source
- Simply Wall Street
Morgan Stanley Smith Barney (PSNL) files Rule 144 to sell 100,000 shares on 07/09/2026
Morgan Stanley Smith Barney LLC filed a Rule 144 notice to sell 100,000 shares of Personalis, Inc. (PSNL) common stock, valued at $1,411,000. This proposed sale on July 9, 2026, follows the exercise of stock options for cash. The filing also details recent 10b5-1 sales by Christo
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 09 Jul 2026 20:09
- Source
- Stock Titan
PSNL Maintained by Morgan Stanley -- Price Target Raised to $13.
Morgan Stanley has maintained an Equal-Weight rating on Personalis (PSNL) but raised its price target from $9.00 to $13.00, an increase of 44.44%. Despite this, GuruFocus assesses PSNL as significantly overvalued by 614.7%, with a current price of $14.87 against a GF Value™ of $2
- Tone
- Negative 39/100
- Event
- Analyst action
- Published
- 09 Jul 2026 18:09
- Source
- GuruFocus
Personalis, Inc. Stock 12‑Month Price Target Raised to $11.43, Implies 19% Downside
Analysts have raised the 12-month average price target for Personalis, Inc. (PSNL) stock from $10.86 to $11.43, with individual forecasts ranging from $10 to $13 per share. Despite this increase, the new target implies a potential 19% downside based on the most recent closing pri
- Tone
- Negative 39/100
- Event
- Analyst action
- Published
- 09 Jul 2026 13:09
- Source
- TradingView
Personalis stock hits 52-week high at 14.24 USD
Personalis Inc. (PSNL) stock reached a new 52-week high of $14.24, reflecting a significant 1-year increase of 107.19%. Despite this surge and strong investor confidence, InvestingPro analysis suggests the stock might be overvalued, although three analysts have revised earnings u
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 06 Jul 2026 15:12
- Source
- Investing.com
Is Personalis (PSNL) Fully Valued Following Its Sharp Share Price Run?
Personalis (PSNL) has seen significant share price appreciation over various timeframes but continues to report net losses, raising questions about its current valuation. While the company is involved in strategic partnerships and operational improvements, a common narrative sugg
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jul 2026 04:56
- Source
- Simply Wall Street
Form 4 Personalis Inc For: 29 June By Investing.com
This article from Investing.com reports the filing of a Form 4 for Personalis Inc. on June 29th. The content is brief, primarily serving as an announcement of the filing and referencing the company's stock symbol PSNL. The article appears to be an automated notification from Inve
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 30 Jun 2026 17:41
- Source
- Investing.com Nigeria
Personalis (PSNL) CFO trades 4,982 shares under Rule 10b5-1 plan
Personalis, Inc. CFO and COO Aaron Tachibana reported an exercise-and-sell transaction involving 4,982 shares of company stock. He exercised stock options at $5.32 per share and subsequently sold the shares in an open-market sale for $14.00 per share. These transactions were exec
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 30 Jun 2026 07:39
- Source
- Stock Titan
PSNL (NASDAQ: PSNL) files Rule 144 to sell 4,982 shares via option exercise
Personalis, Inc. (PSNL) filed a Rule 144 notice to sell 4,982 shares of Common Stock through an option exercise scheduled for June 29, 2026. The filing also detailed prior 10b5-1 sales by Aaron Tachibana, totaling 129,050 shares across three trades in May-June 2026, with an aggre
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 30 Jun 2026 00:39
- Source
- Stock Titan
Price to earnings forward of Personalis, Inc. – NASDAQ:PSNL
This article provides a brief overview of Personalis, Inc. (NASDAQ:PSNL) focusing on its forward price-to-earnings ratio. The content is primarily a data page from TradingView, displaying the stock ticker and linking to financial information, news, and other market data without o
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 28 Jun 2026 06:39
- Source
- TradingView
Price to sales forward of Personalis, Inc. – NASDAQ:PSNL
This page provides financial information for Personalis, Inc. (NASDAQ: PSNL), specifically focusing on its price-to-sales forward ratio. It also highlights various tools and resources available on the TradingView platform for market analysis and trading. The content seems to be b
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Jun 2026 18:10
- Source
- TradingView
Personalis | 4: Statement of changes in beneficial ownership of securities-Officer Tachibana Aaron
This article concerns a Statement of Changes in Beneficial Ownership of Securities (Form 4) filed by Aaron Tachibana, an officer at Personalis. This filing indicates a change in his ownership of Personalis securities. The content of the article is the "Document" itself, implying
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Jun 2026 16:12
- Source
- Moomoo